Too Earlier to Write Off bluebird bio's (BLUE) LentiGlobin in Subset - Cowen

bluebird bio (BLUE) Price Target Reduced to $149 at BofA/Merrill Lynch

November 6, 2015 7:34 AM EST

BofA/Merrill Lynch maintained a Buy rating on bluebird bio (NASDAQ: BLUE) but lowered its price target to $149.00 (from $241.00). Analyst Ying Huang reduced the addressable market for BB305 to 50% in severe thalassemia patients ineligible for stem cell transplant and lowered approval probability to 42%... More

bluebird bio (BLUE) LentiGlobin is Here To Stay, Roth Capital Says; PT Cut to $165

November 5, 2015 1:27 PM EST

Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating but lowered its price target on bluebird bio (NASDAQ: BLUE) to $165.00 (from $192.00) following ASH abstracts. The analyst said LentiGlobin is here to stay.

Chattopadhyay commented, "The kinetics of response in patients with no... More

bluebird bio (BLUE) LentiGlobin 'Does Work', Maxim Group Says

November 5, 2015 1:06 PM EST

Maxim Group analyst Jason McCarthy reiterated a Buy rating and $190 price target on bluebird bio (NASDAQ: BLUE) following today's ASH abstracts. He higlights that SCD and Beta Thal are not the same, exclaiming "it does work."

McCarthy highlighted:

bluebird reported 3Q with a net loss of $42M. The company has $900M in cash,... More

bluebird bio (BLUE) Most Severe Beta-Thal Patients Presenting Challenges, Wedbush Comments; PT Lowered to $165

November 5, 2015 12:39 PM EST

Wedbush analyst David Nierengarten reiterated an Outperform rating on bluebird bio (NASDAQ: BLUE) following today's ASH abstract update but cut his price target to $165.00 (from $222.00). The analyst said the most severe beta-thal patients are presenting challenges.

Nierengarten commented, "Three LentiGlobin abstracts at ASH: Continued transfusion independence in majority of beta-thal patients but most severe patients not there (yet). Our view is that there is increased risk to the programs clinical/regulatory approval timing and... More

'Not Time to Hit Panic Button' on bluebird bio (BLUE), Oppenheimer Says

November 5, 2015 12:23 PM EST

Oppenheimer analyst Wendy Lam is out with her second defense of bluebird bio (NASDAQ: BLUE) today amid the 20% sell-off. Lam said "it is not time to hit the "panic button."

Lam commented, "In ASH abstracts published this morning, BLUE provided an update on... More

bluebird bio (BLUE) Post-ASH Abstract Sell-Off an 'Overreaction', Oppenheimer Says

November 5, 2015 11:00 AM EST

Oppenheimer analyst Wendy Lam weighed in on bluebird bio (NASDAQ: BLUE), saying the Post-ASH abstract sell-off is overdone.

Lam commented, "BLUE published six ASH abstracts this morning, three of which were focused on LentiGlobin in beta-thalassemia and sickle cell disease. Key updates disclosed in the abstracts include new data from additional patients treated in the Northstar and HBG-205... More

bluebird bio (BLUE) Plunges 14% in Early Trade Following ASH Update

November 5, 2015 8:20 AM EST

bluebird bio (NASDAQ: BLUE) is plunging 13.6% in pre-open trading following an update at ASH.

From the company's press release this morning:

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies, announced that data from its ongoing clinical... More